Concerted Suppression of STAT3 and GSK3β Is Involved in Growth Inhibition of Non-Small Cell Lung Cancer by Xanthatin
Open Access
- 28 November 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11) , e81945
Abstract
Xanthatin, a sesquiterpene lactone purified from Xanthium strumarium L., possesses prominent anticancer activity. We found that disruption of GSK3β activity was essential for xanthatin to exert its anticancer properties in non-small cell lung cancer (NSCLC), concurrent with preferable suppression of constitutive activation of STAT3. Interestingly, inactivation of the two signals are two mutually exclusive events in xanthatin-induced cell death. Moreover, we surprisingly found that exposure of xanthatin failed to trigger the presumable side effect of canonical Wnt/β-Catenin followed by GSK3β inactivation. We further observed that the downregulation of STAT3 was required for xanthatin to fine-tune the risk. Thus, the discovery of xanthatin, which has ability to simultaneously orchestrate two independent signaling cascades, may have important implications for screening promising drugs in cancer therapies.Keywords
This publication has 44 references indexed in Scilit:
- Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastomaNeuro-Oncology, 2013
- GSK-3 and mitochondria in cancer cellsFrontiers in Oncology, 2013
- Selective growth inhibition by glycogen synthase kinase-3 inhibitors in tumorigenic HeLa hybrid cells is mediated through NF-κB-dependent GLUT3 expressionOncogenesis, 2012
- Xanthatin Induces Cell Cycle Arrest at G2/M Checkpoint and Apoptosis via Disrupting NF-κB Pathway in A549 Non-Small-Cell Lung Cancer CellsMolecules, 2012
- Nucleocytoplasmic Shuttling of Cytoskeletal Proteins: Molecular Mechanism and Biological SignificanceInternational Journal of Cell Biology, 2011
- Celecoxib Promotes c-FLIP Degradation through Akt-Independent Inhibition of GSK3Cancer Research, 2011
- STAT3 SIGNALING: Anticancer Strategies and ChallengesMolecular Interventions, 2011
- GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell lineJournal of Neuro-Oncology, 2010
- Glycogen synthase kinase 3 beta: can it be a target for oral cancerMolecular Cancer, 2010
- Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3βMolecular Cancer Therapeutics, 2009